Amendments to the Claims

Following is the current listing of claims. This listing of claims will replace all prior versions, and listings, of claims in this application.

Listing of Claims:

1. (Canceled)

2. (Currently Amended) A ~~selective antagonist to~~ denatured collagen type-IV ~~selective peptide antagonist~~ wherein said antagonist is a peptide comprising a core amino acid sequence SEQ ID NO. 1: L-K-Q-N-G-G-N-F-S-L.

3-5. (Canceled)

6. (Currently Amended) The antagonist of claim 2 wherein the binding affinity of the ~~denatured collagen type-IV selective~~ antagonist to denatured type-IV collagen is substantially greater than the binding affinity of said antagonist to native collagen type-IV.

7. (Currently Amended) The antagonist of claim 2 wherein the binding affinity of the ~~selective denatured collagen type-IV~~ antagonist to denatured type-IV collagen is 100-fold greater than the binding affinity of said antagonist to native collagen.

8. (Currently Amended) The antagonist of claim 2 wherein the ~~selective denatured collagen type-IV~~ antagonist inhibits cellular interaction with denatured collagen type-IV.

9. (Currently Amended) A pharmaceutical composition comprising an ~~a selective denatured collagen type-IV~~ antagonist according to Claim 2 and a pharmaceutically acceptable excipient.

10. (Original) The pharmaceutical composition of claim 9 wherein the composition comprises a cytotoxic agent.

11. (Original) The pharmaceutical composition of claim 9 wherein the composition comprises a radioactive material.

12. (Original) The pharmaceutical composition of claim 9 wherein the composition comprises a cytostatic agent.

13-37. (Canceled)

38. (New) An antagonist selective for denatured collagen type-IV, wherein said antagonist is a polypeptide comprising a core amino acid sequence SEQ ID NO. 1: L-K-Q-N-G-G-N-F-S-L.